Protein aggregation: Pathways, induction factors and analysis

Journal of Pharmaceutical Sciences

Volumn 98, Issue 9, 2009, Pages 2909-2934

  Mahler, Hanns Christian ^a   Friess, Wolfgang ^b   Grauschopf, Ulla ^a   Kiese, Sylvia ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Analytical ultra centrifugation; Light scattering; Molecular weight determination; Orthogonal methods; Particle sizing; Protein aggregation; Protein analysis; Protein formulation; SDS PAGE; Size exclusion chromatography

Indexed keywords

PROTEIN DERIVATIVE;

DRUG FORMULATION; HUMAN; NONHUMAN; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN INDUCTION; PROTEIN STRUCTURE; REVIEW;

EID: 68949085124     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21566     Document Type: Review

References (226)

1. Pavlou AK, Belsey MJ. 2005. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59:389-396.
2. Walsh G. 2005. Biopharmaceuticals: Recent approvals and likely directions. Trends Biotechnol 23:553-558. (Pubitemid 41483772)
3. Rosenberg A. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E508. (Pubitemid 44294011)
4. Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20:vi3-vi9.
5. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740. (Pubitemid 35440946)
6. Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371. (Pubitemid 43241978)
7. USP. 2008. USP/NF general chapter 〈788〉 particulate matter in injections. ed. Rockville, MD: United States Pharmacopeial Convention.
8. Ph. Eur. 2008. 2.9.19. Particulate contamination: Sub-visible particles, 6th edition. European Directorate for the Quality of Medicine (EDQM).
9. Ph. Eur. 2008. 2.9.20. Particulate contamination: Visible particles, 6th edition. European Directorate for the Quality of Medicine (EDQM).
10. Philo JS. 2003. Characterizing the aggregation and conformation of protein therapeutics. Am Biotechnol Lab 2003:22-26.
11. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 08:E572-E579.
12. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98:927-938.
13. Kiese S, Papppenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
14. van Buren N, Rehder D, Gadgil H, Matsumara M, Jacob J. 2008. Elucidation of two major aggregation pathways in an IgG2 antibody. J Pharm Sci DOI: 10.1002/jps.21514.
15. Krishnan S, Chi EY, Webb JN, Chang BS, Shan D, Goldenberg M, Manning MC, Randolph TW, Carpenter JF. 2002. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41:6422-6431. (Pubitemid 34526008)
16. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL. 2008. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47:5088-5100. (Pubitemid 351620747)
17. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309:236-255. (Pubitemid 29446453)
18. Mahler H-C, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59:407-417. (Pubitemid 40342515)
19. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30. (Pubitemid 40093537)
20. Karshikoff A. 2006. Non-covalent interactions in proteins. 1st edition. London: Imperial College Press. p 348.
21. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5:E10.
22. Shahrokh Z, Eberlein G, Buckley D, Paranandi MV, Aswad DW, Stratton P, Mischak R, Wang YJ. 1994. Major degradation products of basic fibroblast growth factor: Detection of succinimide and iso-aspartate in place of aspartate15. Pharm Res 11:936-944. (Pubitemid 24227636)
23. Malencik DA, Anderson SR. 2003. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 25:233-247. (Pubitemid 38041262)
24. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94:1928-1940. (Pubitemid 41551477)
25. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12:903-913. (Pubitemid 36505425)
26. Arakawa T, Timasheff SN. 1985. The stabilization of proteins by osmolytes. Biophys J 47:411-414.
27. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. 1998. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci 87:1069-1076. (Pubitemid 28452105)
28. Calamai M, Canale C, Relini A, Stefani M, Chiti F, Dobson CM. 2005. Reversal of protein aggregation provides evidence for multiple aggregated states. J Mol Biol 346:603-616.
29. Arakawa T, Bhat R, Timasheff SN. 1990. Preferential interactions determine protein solubility in three-component solutions: The MgCl2 system. Biochemistry 29:1914-1923. (Pubitemid 20074740)
30. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. 2001. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 46:307-326. (Pubitemid 33653426)
31. Andrews JM, Roberts CJ. 2007. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J Phys Chem B 111:7897-7913.
32. Ferrone FA. 1999. Analysis of protein aggregation kinetics. Methods in enzymology. In: Wetzel R, editor. Amyloid, prions, and other protein aggregates, volume 309. edition. San Diego, CA: Academic Press. pp 256-274.
33. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256-274. (Pubitemid 40293323)
34. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2008. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci epub.
35. Chiti F, Dobson C. 2006. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366. (Pubitemid 44118036)
36. Ferrone FA, Rotter MA. 2004. Crowding and the polymerization of sickle hemoglobin. J Mol Recognit 17:497-504.
37. Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564-E571.
38. Moore JMR, Patapoff TW, Cromwell MEM. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38:13960-13967. (Pubitemid 29504227)
39. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188. (Pubitemid 29392904)
40. Minton AP. 2005. Influence of macromolecular crowding upon the stability and state of association of proteins: Predictions and observations. J Pharm Sci 94:1668-1675.
41. Kelly JW. 1998. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101-106.
42. Marcon G, Plakoutsi G, Chiti F. 2006. Protein aggregation starting from the native globular state, methods in enzymology. In: Kheberpal I, Wetzel R, editors. Amyloid, prions, and other protein aggregates, Part C, Volume 413. edition. Academic Press. pp 75-91.
43. Holm NK, Jespersen SK, Thomassen LV, Wolff TY, Sehgal P, Thomsen LA, Christiansen G, Andersen CB, Knudsen AD, Otzen DE. 2007. Aggregation and fibrillation of bovine serum albumin. Biochim Biophys Acta Proteins Proteomics 1774:1128-1138. (Pubitemid 47333256)
44. Johansson J. 2005. Amyloid fibrils. FEBS J 272:5941.
45. Makin OS, Serpell LC. 2005. Structures for amyloid fibrils. FEBS J 272:5950-5961.
46. Brange J, Havelund S, Hougaard P. 1992. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 9:727-734.
47. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10:307-377.
48. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, Carpenter JF. 1998. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 87:1597-1603. (Pubitemid 28559648)
49. Hillgren A, Lindgren J, Alden M. 2002. Protection mechanism of Tween 80 during freeze-thawing of a model protein, LDH. Int J Pharm 237:57-69. (Pubitemid 34310479)
50. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. 2007. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97:1801-1812.
51. Strambini GB, Gonnelli M. 2007. Protein stability in ice. Biophys J 92:2131-2138.
52. Lashmar UT, Vanderburgh M, Little SJ. 2007. Bulk freeze-thawing of macromolecules. Effects of cryoconcentration on their formulation and stability. BioProcess International™; 44-54.
53. Pikal-Cleland KA, Cleland JL, Anchordoquy TJ, Carpenter JF. 2002. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J Pharm Sci 91:1969-1979.
54. Cao E, Chen Y, Cui Z, Foster PR. 2003. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol Bioeng 82:684-690. (Pubitemid 36576232)
55. Webb S, Webb J, Hughes T, Sesin D, Kincaid A. 2002. Freezing bulk-scale biopharmaceuticals using common techniques - And the magnitude of freeze-concentration. Biopharm 15:2-8. (Pubitemid 34507126)
56. Bhatnagar BS, Nehm SJ, Pikal MJ, Bogner RH. 2005. Post-thaw aging affects activity of lactate dehydrogenase. J Pharm Sci 94:1382-1388.
57. Virkar PD, Narendranathan TJ, Hoare M, Dunnill P. 1981. Studies of the effect of shear on globular proteins: Extension to high shear fields and to pumps. Biotechnol Bioeng 23:425-429.
58. Maa Y-F, Hsu CC. 1996. Effect of high shear on proteins. Biotechnol Bioeng 51:458-465.
59. Thomas CR, Nienow AW, Dunnill P. 1979. Action of shear on enzymes: Studies with alcohol dehydrogenase. Biotechnol Bioeng 21:2263-2278.
60. Charm SE, Wong BL. 1981. Shear effects on enzymes. Enzyme Microb Technol 3:111-118.
61. Maa Y-F, Hsu CC. 1997. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng 54:503-512.
62. Thomas CR, Dunnill P. 1979. Action of shear on enzymes: Studies with catalase and urease. Biotechnol Bioeng 21:2279-2302.
63. Morel M-H, Redl A, Guilbert S. 2002. Mechanism of heat and shear mediated aggregation of wheat gluten protein upon mixing. Biomacromolecules 3:488-497. (Pubitemid 34567451)
64. Gulseren I, Guzey D, Bruce BD, Weiss J. 2007. Structural and functional changes in ultrasonicated bovine serum albumin solutions. Ultrason Sonochem 14:173-183. (Pubitemid 44500713)
65. Colombie S, Gaunand A, Lindet B. 2001. Lysozyme inactivation under mechanical stirring: Effect of physical and molecular interfaces. Enzyme Microb Technol 28:820-826. (Pubitemid 32530532)
66. Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res 61:137-154. (Pubitemid 39043719)
67. Fields GB, Alonso DOV, Stigter D, Dill KA. 1992. Theory for the aggregation of proteins and copolymers. J Phys Chem 96:3974-3981.
68. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19:511-516.
69. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402. (Pubitemid 38725014)
70. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. 2007. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci 97:3005-3021.
71. Minton AP. 2008. Effective hard particle model for the osmotic pressure of highly concentrated binary protein solutions. Biophys J 94:L57-L59.
72. Roefs SPFM, De Kruif KG. 1994. A model for the denaturation and aggregation of B-lactoglobulin. Eur J Biochem 226:883-889.
73. Liu JAJ, Shire SJ. 2006. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J 08:E580-E589.
74. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation. Pharm Res 20:1325-1336. (Pubitemid 37164039)
75. Idicula-Thomas S, Balaji PV. 2007. Correlation between the structural stability and aggregation propensity of proteins. In Silico Biol 7:225-237. (Pubitemid 47335237)
76. Katayama DS, Nayar R, Chou DK, Valente JJ, Cooper J, Henry CS, Velde DGV, Villarete L, Liu CP, Manning MC. 2006. Effect of buffer species on the thermally induced aggregation of interferon-tau. J Pharm Sci 95:1212-1226. (Pubitemid 43874437)
77. Kameoka D, Masuzaki E, Ueda T, Imoto T. 2007. Effect of buffer species on the unfolding and the aggregation of humanized IgG. J Biochem 142:383-391. (Pubitemid 350221842)
78. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 2: Impact of container closures. Biotechnol Adv 25:318-324.
79. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Chamow SM. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 20:1952-1960. (Pubitemid 38005526)
80. Zhang W, Czupryn MJ, Boyle PT, Amari J. 2002. Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11. Pharm Res 19:1223-1231. (Pubitemid 34985008)
81. Li S, Schöneich C, Borchardt RT. 1995. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48:490-500.
82. Lam X, Yang J, Cleland J. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86:1250-1255. (Pubitemid 27486096)
83. Davies MJ. 2003. Singlet oxygen-mediated damage to proteins and its consequences. Biochem Biophys Res Commun 305:761-770.
84. Kerwin BA. 2007. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci 97:2924-2935.
85. Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA. 2007. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci 96:106-116. (Pubitemid 46087343)
86. EMEA. 2007. Production and Quality Control of Monoclonal Antibodies and Related Substances. EMEA/CHMP/BWP/15763/2007.
87. Porath J, Flodin P. 1959. Gel filtration: A method for desalting and group separation. Nature 183: 1657-1659.
88. Unger K. 1983. The application of size exclusion chromatography to the analysis of biopolymers. Trends Anal Chem 2:271-274. (Pubitemid 14490115)
89. Barth HC. 2004. High-performance SEC column technology. LC GC LC Column Technol Suppl: 43-46.
90. Ye H. 2006. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal Biochem 356:76-85. (Pubitemid 44232732)
91. Wen J, Arakawa T, Philo JS. 1996. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem 240:155-166. (Pubitemid 26304259)
92. Oliva A, Llabrés M, Fariña JB. 2001. Comparative study of protein molecular weights by size-exclusion chromatography and laser-light scattering. J Pharm Biomed Anal 25:833-841. (Pubitemid 32488948)
93. Arakawa T, Philo JS, Ejima D, Tsumoto K, Arisaka F. 2006. Aggregation analysis of therapeutic proteins, Part 1. General aspects and techniques for assessment. BioProcess International; 32-42.
94. Tsumoto K, Ejima D, Kita Y, Arakawa T. 2005. Review: Why is arginine effective in suppressing aggregation? Protein Pept Lett 12:613-619.
95. Maizel JV Jr. 1966. Acrylamide-gel electrophorograms by mechanical fractionation: Radioactive adenovirus proteins. Science 151:988-990.
96. Shapiro AL, Vinuela E, Maizel V, Jacob J. 1967. Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels. Biochem Biophys Res Commun 28:815-820.
97. Schagger H. 2006. Tricine-SDS-PAGE. Nat Protoc 1:16-22.
98. Waehneldt TV. 1975. Sodium dodecyl sulfate in protein chemistry. BioSystems 6:176-187.
99. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
100. Thomas TC, McNamee MG. 1990. Purification of membrane proteins. Guide to protein purification. In: Deutscher MF, editor. Methods in enzymology series 182. San Diego, CA: Academic Press. pp 499-520.
101. Taylor FR, Prentice HL, Garber EA, Fajardo HA, Vasilyeva E, Blake Pepinsky R. 2006. Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem 353:204-208. (Pubitemid 43775437)
102. Schagger H, Aquila H, Von Jagow G. 1988. Coomassie blue-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for direct visualization of polypeptides during electrophoresis. Anal Biochem 173:201-205. (Pubitemid 18213248)
103. Switzer RC, Merril CR, Shifrin S. 1979. A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels. Anal Biochem 98:231-237. (Pubitemid 10235500)
104. Swain M, Ross NW. 1995. A silver stain protocol for proteins yielding high resolution and transparent background in sodium dodecyl sulfate-polyacrylamide gels. Electrophoresis 16:948-951.
105. Steinberg TH, Jones LJ, Haugland RP, Singer VL. 1996. SYPRO orange and SYPRO red protein gel stains: One-step fluorescent staining of denaturing gels for detection of nanogram levels of protein. Anal Biochem 239:223-237.
106. Fishbein WN. 1972. Quantitative densitometry of 1-50 mg protein in acrylamide gel slabs with Coomassie blue. Anal Biochem 46:388-401.
107. Ph. Eur. 2008. 2.2.31. Electrophoresis, 6th edition. European Directorate for the Quality of Medicine (EDQM).
108. Rabilloud T. 1992. A comparison between low background silver diammine and silver nitrate protein stains. Electrophoresis 13:429-439.
109. Won CM, Molnar TE, McKean RE, Spenlehauer GA. 1998. Stabilizers against heat-induced aggregation of RPR 114849, an acidic fibroblast growth factor (aFGF). Int J Pharm 167:25-36.
110. Wang W, Wang YJ, Wang DQ. 2008. Dual effects of Tween 80 on protein stability. Int J Pharm 347:31-38. (Pubitemid 350180316)
111. Reschiglian P, Zattoni A, Roda B, Michelini E, Roda A. 2005. Field-flow fractionation and biotechnology. Trends Biotechnol 23:475-483.
112. Fraunhofer W, Winter G. 2004. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm 58:369-383. (Pubitemid 39037242)
113. Giddings JC. 1993. Field-flow fractionation: Analysis of macromolecular, colloidal, and particulate materials. Science 260:1456-1465.
114. Dulog L, Schauer T. 1996. Field flow fractionation for particle size determination. Prog Org Coatings 28:25-31. (Pubitemid 126405282)
115. Caldwell KD, Kesner LF, Myers MN, Giddings JC. 1972. Electrical field-flow fractionation of proteins. Science 176:296-298.
116. Yohannes G, Sneck M, Varjo SJO, Jussila M, Wiedmer SK, Kovanen PT, Oorni K, Riekkola M-L. 2006. Miniaturization of asymmetrical flow field-flow fractionation and application to studies on lipoprotein aggregation and fusion. Anal Biochem 354:255-265. (Pubitemid 43913566)
117. Litzen A, Wahlund K-G. 1989. Improved separation speed and efficiency for proteins, nucleic acids and viruses in asymmetrical flow field flow fractionation. J Chromatogr A 476:413-421. (Pubitemid 19193639)
118. Wahlund K-G, Giddings JC. 1987. Properties of an asymmetrical flow field-flow fractionation channel having one permeable wall. Anal Chem 59:1332-1339.
119. Williams PS. 1997. Design of an asymmetrical flow field-flow fractionation channel for uniform channel flow velocity. J Microcolumn Separations 9:459-467. (Pubitemid 127460973)
120. Liu J, Andya JD, Shire SJ. 2006. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J 08:E580-E589. (Pubitemid 44507669)
121. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. 2007. Characterization of protein aggregation: The case of a therapeutic immunoglobulin. Biochim Biophys Acta Proteins Proteomics 1774:146-153. (Pubitemid 46055309)
122. Litzén A, Wahlund K-G. 1991. Zone broadening and dilution in rectangular and trapezoidal asymmetrical flow field-flow fractionation channels. Anal Chem 63:1001-1007.
123. Giddings JC. 1990. Hydrodynamic relaxation and sample concentration in field-flow fractionation using permeable wall elements. Anal Chem 62:2306-2312.
124. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96:1-26.
125. Matheus S, Mahler H-C, Friess W. 2006. A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool. Pharm Res 23:1617-1627. (Pubitemid 43993825)
126. Giddings JC, Yang FJ, Myers MN. 1977. Flow field-flow fractionation as a methodology for protein separation and characterization. Anal Biochem 81:394-407.
127. Litzen A, Walter JK, Krischollek H, Wahlund KG. 1993. Separation and quantitation of monoclonal antibody aggregates by asymmetrical flow field-flow fractionation and comparison to gel permeation chromatography. Anal Biochem 212:469-480. (Pubitemid 23245099)
128. Reschiglian P, Zattoni A, Roda B, Cinque L, Melucci D, Min BR, Moon MH. 2003. Hyperlayer hollow-fiber flow field-flow fractionation of cells. J Chromatogr A 985:519-529. (Pubitemid 36164842)
129. Mozersky SM, Caldwell KD, Jones SB, Maleeff BE, Barford RA. 1988. Sedimentation field flow fractionation of mitochondrial and microsomal membranes from corn roots. Anal Biochem 172:113-123.
130. Kassab JR, Cardot PJP, Zahoransky RA, Battu S. 2005. Fast "hyperlayer" separation development in sedimentation field flow fractionation. J Chromatogr B 826:8-16. (Pubitemid 41446428)
131. Parsons R, Yue V, Tong X, Cardot P, Bernard A, Andreux JP, Caldwell K. 1996. Comparative study of human red blood cell analysis with three different field-flow fractionation systems. J Chromatogr B Biomed Sci Appl 686:177-187. (Pubitemid 26402955)
132. Sanz R, Battu S, Puignou L, Galceran MT, Cardot PJP. 2003. Sonication effect on cellular material in sedimentation and gravitational field flow fractionation. J Chromatogr A 1002:145-154. (Pubitemid 36694951)
133. Janca J, Ananieva IA, Menshikova AY, Evseeva TG. 2004. Micro-thermal focusing field-flow fractionation. Journal of Chromatography B 3rd International Symposium on Separations in the BioSciences: 100 Years of Chromatography 800:33-40.
134. Caldwell KD, Gao Y-S. 1993. Electrical field-flow fractionation in particle separation. 1. Monodisperse standards. Anal Chem 65:1764-1772.
135. Carpino F, Moore LR, Zborowski M, Chalmers JJ, Williams PS. 2005. Analysis of magnetic nanoparticles using quadrupole magnetic field-flow fractionation. Journal of Magnetism and Magnetic Materials Proceedings of the 5th International Conference on Scientific and Clinical Applications of Magnetic Carriers 293: 546-552. (Pubitemid 40608978)
136. Varley PG, Brown AJ, Dawkes HC, Burns NR. 1997. A case study and use of sedimentation equilibrium analytical ultracentrifugation as a tool for biopharmaceutical development. Eur Biophys J 25:437-443.
137. Rivas G, Stafford W, Minton AP. 1999. Characterization of heterologous protein-protein interactions using analytical ultracentrifugation. Methods 19:194-212. (Pubitemid 29515855)
138. Schuck P. 2003. On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. Anal Biochem 320:104-124. (Pubitemid 36937072)
139. Liu J, Shire SJ. 1999. Analytical ultracentrifugation in the pharmaceutical industry. J Pharm Sci 88:1237-1241.
140. Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11:2067-2079. (Pubitemid 34919611)
141. Berkowitz SA. 2006. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J 08:E590-E605.
142. Howlett GJ, Minton AP, Rivas G. 2006. Analytical ultracentrifugation for the study of protein association and assembly. Curr Opin Chem Biol Anal Tech/Mech 10:430-436. (Pubitemid 44375070)
143. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96:268-279. (Pubitemid 46363558)
144. Laue T. 2004. Analytical ultracentrifugation: A powerful 'new' technology in drug discovery. Drug Discov Today Technol 1:309-315.
145. Svedberg T, Pedersen KO. 1940. The ultracentrifuge. New York: Johnson Reprint Corp. p 478.
146. Laue TM, Stafford WF III. 1999. Modern applications of analytical ultracentrifugation. Annu Rev Biophys Biomol Struct 28:75-100.
147. Gabrielson JP, Randolph TW, Kendrick BS, Stoner MR. 2007. Sedimentation velocity analytical ultracentrifugation and SEDFIT/c(s): Limits of quantitation for a monoclonal antibody system. Anal Biochem 361:24-30.
148. Pekar A, Sukumar M. 2007. Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: Practical considerations that affect precision and accuracy. Anal Biochem 367:225-237. (Pubitemid 47001925)
149. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. 2002. Size-distribution analysis of proteins by analytical ultracentrifugation: Strategies and application to model systems. Biophys J 82:1096-1111. (Pubitemid 34111246)
150. Vistica J, Dam J, Balbo A, Yikilmaz E, Mariuzza RA, Rouault TA, Schuck P. 2004. Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem 326:234-256. (Pubitemid 38293385)
151. Lamm O. 1929. Die Differentialgleichung der Ultrazentrifugierung. Ark Mat Astr Fys 21:1-4.
152. Cole J, Hansen J. 1999. Analytical ultracentrifugation as a contemporary biomolecular research tool. J Biomol Tech 10:163-176.
153. Lu Y, Harding SE, Turner A, Smith B, Athwal DS, Grossmann JG, Davis KG, Rowe AJ. 2007. Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci 97:2062-2079.
154. Kiese S, Pappenberger A, Friess W, Mahler H-C. 2008. Shaking versus stirring: Protein aggregation of an IgG1. Poster presentation at AAPS National Biotechnology Conference 2008, Toronto, Canada.
155. Sukumar M. 2008. Assessing aggregation during formulation and purification process development. Presentation at BioProcess International Conference, Vienna, Austria.
156. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to non-covalent association. Pharm Res 21:1087-1093. (Pubitemid 38954191)
157. Kunitani M, Wolfe S, Rana S, Apicella C, Levi V, Dollinger G. 1997. Classical light scattering quantitation of protein aggregates: Off-line spectroscopy versus HPLC detection. J Pharm Biomed Anal 16:573-586. (Pubitemid 28044189)
158. Eckhardt BM, Oeswein JQ, Yeung DA, Milby TD, Bewley TA. 1994. A turbidimetric method to determine visual appearance of protein solutions. J Pharm Sci Technol 48:64-70.
159. Eberlein GA, Stratton PR, Wang YJ. 1994. Stability of rhbFGF as determined by UV spectroscopic measurements of turbidity. PDA J Pharm Sci Technol 48:224-230.
160. Arvinte T, Bui TTT, Dahab AA, Demeule B, Drake AF, Elhag D, King P. 2004. The multi-mode polarization modulation spectrometer: Part 1: Simultaneous detection of absorption, turbidity, and optical activity. Anal Biochem 332:46-57. (Pubitemid 39099470)
161. Laos K, Brownsey GJ, Ring SG. 2007. Interactions between furcellaran and the globular proteins bovine serum albumin and [beta]-lactoglobulin. Carbohydr Polym 67:116-123. (Pubitemid 44738033)
162. Yu C-M, Chin CY, Franses EI, Wang N-HL. 2006. In situ probing of insulin aggregation in chromatography effluents with spectroturbidimetry. J Colloid Interface Sci 299:733-739.
163. Lee D-W, Hong Y-H, Choe E-A, Lee S-J, Kim S-B, Lee H-S, Oh J-W, Shin H-H, Pyun Y-R. 2005. A thermodynamic study of mesophilic, thermophilic, and hyperthermophilic l-arabinose isomerases: The effects of divalent metal ions on protein stability at elevated temperatures. FEBS Lett 579:1261-1266.
164. Cromwell ME. 2008. Opalescence: A Clarifying Case Study. Presentation at BioProcess International Conference, Vienna, Austria.
165. Ph. Eur. 2008. 2.2.1. Clarity and degree of opalescense of liquids, 6th edition. European Directorate for the Quality of Medicine (EDQM).
166. Murphy R, Amos T, editors. 2006. Misbehaving proteins: Protein (MIS) folding, aggregation, and stability. Springer-Verlag New York Inc.
167. Mauro M, Craparo EF, Podesta A, Bulone D, Carrotta R, Martorana V, Tiana G, San Biagio PL. 2007. Kinetics of different processes in human insulin amyloid formation. J Mol Biol 366:258-274. (Pubitemid 46123327)
168. Gun'ko VM, Klyueva AV, Levchuk YN, Leboda R. 2003. Photon correlation spectroscopy investigations of proteins. Adv Colloid Interface Sci 105:201-328.
169. Debye P. 1947. Molecular-weight determination by light scattering. J Phys Chem 51:18-32.
170. Ahrer K, Buchacher A, Iberer G, Josic D, Jungbauer A. 2003. Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering. Journal of Chromatography A 22nd International Symposium on the Separation of Proteins, Peptides and Polynucleotides 1009:89-96. (Pubitemid 36969802)
171. Tsai AM, van Zanten JH, Betenbaugh MJ. 1998. Study of protein aggregation due to heat denaturation: A structural approach using circular dichroism spectroscopy, nuclear magnetic resonance, and static light scattering. Biotechnol Bioeng 59:273-280.
172. Ramzi A, Sutter M, Hennink WE, Jiskoot W. 2006. Static light scattering and small-angle neutron scattering study on aggregated recombinant gelatin in aqueous solution. J Pharm Sci 95:1703-1711. (Pubitemid 44229577)
173. Ahrer K, Buchacher A, Iberer G, Jungbauer A. 2004. Detection of aggregate formation during production of human immunoglobulin G by means of light scattering. Journal of Chromatography A 23rd International Symposium on the Separation of Proteins, Peptides and Polynucleotides 1043:41-46. (Pubitemid 38952774)
174. Georgalis Y, Saenger W. 1999. Light scattering studies on supersaturated protein solutions. Sci Prog 82:271-294.
175. Scherer T, Kanai S, Liu J, Shire SJ. 2007. Characterization of monoclonal antibodies at high concentrations by light scattering. Presentation at AAPS National Biotechnology Conference 2007, San Diego, CA, USA.
176. Zhu R, Frankema W, Huo Y, Kok WT. 2005. Studying protein aggregation by programmed flow field-flow fractionation using ceramic hollow fibers. Anal Chem 77:4581-4586. (Pubitemid 41542281)
177. Wyatt PJ. 1993. Mean square radius of molecules and secondary instrumental broadening. J Chromatogr A 648:27-32.
178. Qian RL, Mhatre R, Krull IS. 1997. Characterization of antigen-antibody complexes by size-exclusion chromatography coupled with low-angle light-scattering photometry and viscometry. J Chromatogr A 787:101-109. (Pubitemid 27515129)
179. Georgalis Y, Zouni A, Eberstein W, Saenger W. 1993. Formation dynamics of protein precrystallization fractal clusters. J Crystal Growth 126:245-260. (Pubitemid 23614022)
180. Onuma K, Kanzaki N. 2003. Size distribution and intermolecular interaction of laminin-1 in physiological solutions. J Phys Chem B 107:11799-11804.
181. Onuma K, Kanzaki N. 2005. Aggregation dynamics of laminin-1 in a physiological solution: A time-resolved static light scattering study. J Crystal Growth 284:530-537. (Pubitemid 41406322)
182. Plakoutsi G, Bemporad F, Calamai M, Taddei N, Dobson CM, Chiti F. 2005. Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J Mol Biol 351:910-922. (Pubitemid 41111905)
183. Patapoff TW, Tani TH, Cromwell MEM. 1999. A low-volume, short-path length dynamic light scattering sample cell for highly turbid suspensions. Anal Biochem 270:338-340.
184. Fujime S, Takasaki-Ohsita M, Miyamoto S. 1988. Dynamic light scattering from polydisperse suspensions of thin ellipsoidal shells of revolution with submicron diameters. Biophys J 53:497-503.
185. Khlebtsov NG, Melnikov AG, Bogatyrev VA. 1999. Relaxation optic phenomena in polydisperse suspensions and determination of particle sizes using transmitted light parameters. Colloids Surf A Physicochem Eng Aspects 148:17-28.
186. Coulter WH. 1953. Means for Counting Particles Suspended in a Fluid.
187. Henriquez RR, Ito T, Sun L, Crooks RM. 2004. The resurgence of coulter counting for analyzing nanoscale objects. Analyst 129:478-482. (Pubitemid 38813510)
188. Pavanetto F, Conti B, Genta I, Ponci R, Montanari L, Vianello S. 1989. Particulate matter contamination of small volume parenterals. Int J Pharm 51:55-61. (Pubitemid 19087832)
189. Etzler FM, Sanderson MS. 1995. Particle size analysis: A comparative study of various methods. Part Part Syst Characterization 12:217-224.
190. Coa S, Pollastrini J, Jiao N, Jiang Y, Narhi L. 2007. Quantitative determination of subvisible particles in injections using a small volume light obscuration method. Poster presentation at AAPS National Biotechnology Conference 2007, San Diego, CA, USA.
191. JP. 2001. Japanese Pharmacopoeia, 14th edition. Tokyo: Yakuji Nippo Ltd. pp 1-848.
192. Blackwell HR. 1946. Contrast thresholds of the human eye. J Opt Soc Am 36:624-643.
193. Kerker M. 1987. Classics and classicists of colloid and interface science: John Tyndall. J Colloid Interface Sci 119:602-604.
194. Gentry JW, Jui-Chen L. 1996. The legacy of John Tyndall in aerosol science. J Aerosol Sci 27:S503-S504.
195. Barber TA, Lannis MD, Williams JG. 1989. Method evaluation: Automated microscopy as a compendial test for particulates in parenteral solutions. PDA J Pharm Sci Technol 43.
196. Sharma D, King D, Thomas D, Oma P. 2007. Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids. Eur J Paranteral Pharm Sci 12:97-101.
197. Sharma D, King D, Thomas D, Oma P. 2007. Evaluation of flow microscopy test protocol for analysis of sub-visible particles in parenteral samples. Poster presentation at AAPS National Biotechnology Conference 2007, San Diego, CA, USA.
198. Dukhin AS, Goetz PJ, van de Ven TGM. 2006. Ultrasonic characterization of proteins and blood cells. Colloids Surf B Biointerfaces 53:121-126.
199. Sarvazyan AP. 1991. Ultrasonic velocimetry of biological compounds. Annu Rev Biophys Biophys Chem 20:321-342.
200. Beckman. 1995. The Sizing of Non-Spherical, Sub-Micron Particles Using Polarization Intensity Differential Scattering (PIDS). Beckman Coulter Application Information A-1995A.
201. Gustav M. 1908. Sättigungsstrom und Stromkurve einer schlecht leitenden Flüssigkeit. Annalen der Physik 331:597-614.
202. Hawe A, Sutter M, Jiskoot W. 2008. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25:1487-1499.
203. Demeule B, Lawrence MJ, Drake AF, Grumy R, Arvinte T. 2007. Characterization of protein aggregation. The case of a therapeutic immunoglobulin. Biochemica et Biophysica Acta 177:146-153.
204. Linke RP. 2000. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Archiv 436:439-448.
205. Bely M, Makovitzky J. 2006. Sensitivity and specificity of Congo red staining according to Romhanyi. Comparison with Puchtler's or Bennhold's methods. Acta Histochemica Special issue of Acta Histochemica to celebrate the 100th anniversary of the birth of George Romh'nyi (1905-1991). 108:175-180.
206. Ban T, Hamada D, Hasegawa K, Naiki H, Goto Y. 2003. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J Biol Chem 278:16462-16465. (Pubitemid 36799502)
207. Puchtler H, Sweat F, Levine M. 1962. On the binding of Congo red to amyloid. J Histochem Cytochem 10:355-364.
208. Westermark GT, Johnson KH, Westermark P. 1999. Staining methods for identification of amyloid in tissue: Methods in enzymology. In: Wetzel R, editor. Amyloid, prions, and other protein aggregates, Volume 309. edition. San Diego, CA: Academic Press. pp 3-25.
209. Nilsson MR. 2004. Techniques to study amyloid fibril formation in vitro. Method investigating protein folding, misfolding and nonnative states: Experimental and theoretical methods 34:151-160. (Pubitemid 38993215)
210. Sutter M, Oliveira S, Sanders N, Lucas B, van Hoek A, Hink M, Visser A, De Smedt S, Hennink W, Jiskoot W. 2007. Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye nile red. J Fluorescence 17:181-192. (Pubitemid 46355026)
211. Kotik M, Zuber H. 1992. Evidence for temperature-dependent conformational changes in the L-lactate dehydrogenase from Bacillus stearothermophilus. Biochemistry 31:7787-7795.
212. Hungerford G, Rei A, Ferreira MIC. 2005. Studies on the interaction of Nile red with horseradish peroxidase in solution. FEBS J 272:6161-6169. (Pubitemid 41713705)
213. Sackett DL, Wolff J. 1987. Nile red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces. Anal Biochem 167:228-234.
214. Kundu B, Guptasarma P. 1999. Hydrophobic dye inhibits aggregation of molten carbonic anhydrase during thermal unfolding and refolding. Proteins Structure Funct Genet 37:321-324. (Pubitemid 29519723)
215. Engelhard M, Evans PA. 1995. Kinetics of interaction of partially folded proteins with a hydrophobic dye: Evidence that molten globule character is maximal in early folding intermediates. Protein Sci 4:1553-1562.
216. Okada T, Wakabayashi M, Ikeda K, Matsuzaki K. 2007. Formation of toxic fibrils of Alzheimer's Amyloid [beta]-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J Mol Biol 371:481-489. (Pubitemid 47048280)
217. Nielsen L, Frokjaer S, Carpenter JF, Brange J. 2001. Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. J Pharm Sci 90:29-37. (Pubitemid 32050474)
218. Taschner N, Muller SA, Alumella VR, Goldie KN, Drake AF, Aebi U, Arvinte T. 2001. Modulation of antigenicity related to changes in antibody flexibility upon lyophilization. J Mol Biol 310:169-179. (Pubitemid 32619960)
219. Ma H, Shieh K-J, Qiao TX. 2006. Study of Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM). Nat Sci 4:14-22.
220. Frederix P, Akiyama T, Staufer U, Gerber C, Fotiadis D, Muller D, Engel A. 2003. Atomic force bio-analytics. Curr Opi Chem Biol 7:641-647.
221. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG. 2006. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45:15157-15167. (Pubitemid 46032442)
222. Stine WB, Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ, Holzman TF, Krafft GA. 1996. The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem 15:193-203. (Pubitemid 3040251)
223. Grudzielanek S, Velkova A, Shukla A, Smirnovas V, Tatarek-Nossol M, Rehage H, Kapurniotu A, Winter R. 2007. Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways. J Mol Biol 370:372-384. (Pubitemid 46829214)
224. Chen Y, Cai J, Xu Q, Chen ZW. 2004. Atomic force bio-analytics of polymerization and aggregation of phycoerythrin-conjugated immunoglobulin G molecules. Mol Immunol 41:1247-1252. (Pubitemid 39346273)
225. Pelton JT, McLean LR. 2000. Spectroscopic methods for analysis of protein secondary structure. Anal Biochem 277:167-176. (Pubitemid 30055864)
226. rap-ID. Application Note. Identification of foreign particles in small volume parenterals.